October 13, 2018

ADTX: Aditxt, Inc. Stock

by Wilton Risenhoover

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M)	1.84
Enterprise Value ($M)	14.60
Book Value ($M)	15.76
Book Value / Share	7.15
Price / Book	0.22
NCAV ($M)	-21.86
NCAV / Share	-18.86
Price / NCAV	-0.08

Profitability (mra)
Return on Invested Capital (ROIC)	-2.27
Return on Assets (ROA)	-1.23
Return on Equity (ROE)	-3.52

Liquidity (mrq)
Quick Ratio	0.08
Current Ratio	0.09

Balance Sheet (mrq) ($M)
Current Assets	1.22
Assets	31.22
Liabilities	15.46
Debt	n/a
Equity	n/a

Income Statement (mra) ($M)
Revenue	0.13
Operating Income	-27.86
Net Income	-34.45

Cash Flow Statement (mra) ($M)
Cash From Operations	-16.76
Cash from Investing	-5.00
Cash from Financing	22.50
(click for more detail)

Top 13F Investors	Shares (1000)	Change (%)	Value ($1000)	Change (%)
(click for more detail)

Date	Insider Trades	Code	Shares	Value
(click for more detail)

File Date	Form	SEC Filings
2025-05-15	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT P
2025-03-31	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For fiscal year ended: December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION
2024-11-18	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPO
2024-08-19	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PU
2024-05-20	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT P
(click for more detail)

Short Volume
Market Date	Short Volume	Total Volume	Short Volume Ratio
2025-05-15	19,988	43,530	45.92
2025-05-14	26,169	72,755	35.97
2025-05-13	22,415	86,538	25.90
2025-05-12	25,153	73,245	34.34
(click for more detail)

Similar Companies
ACHV – Achieve Life Sciences, Inc.	ACXP – Acurx Pharmaceuticals, Inc.
ADIL – Adial Pharmaceuticals, Inc.	ADVM – Adverum Biotechnologies, Inc.
AGEN – Agenus Inc.

Financial data and stock pages provided by
Fintel.io

Related